Moderna, Inc. $MRNA Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Moderna, Inc. (NASDAQ:MRNA) by 15.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,040,117 shares of the company’s stock after buying an additional 410,252 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.78% of Moderna worth $83,877,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of MRNA. S Bank Fund Management Ltd purchased a new position in Moderna in the first quarter valued at $25,000. Rothschild Investment LLC raised its position in Moderna by 94.1% in the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after purchasing an additional 446 shares in the last quarter. TD Private Client Wealth LLC raised its position in Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after purchasing an additional 743 shares in the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of Moderna in the 2nd quarter valued at about $26,000. Finally, SVB Wealth LLC acquired a new position in shares of Moderna during the first quarter worth about $28,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Citigroup decreased their price target on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. UBS Group restated a “buy” rating on shares of Moderna in a report on Friday, November 21st. Piper Sandler reiterated an “overweight” rating and set a $63.00 target price (down previously from $69.00) on shares of Moderna in a research note on Friday, November 21st. Bank of America dropped their target price on Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, November 10th. Finally, Morgan Stanley lifted their price target on Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday, October 10th. Two research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $29.46.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $25.84 on Friday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $48.92. The firm has a market capitalization of $10.10 billion, a P/E ratio of -3.20 and a beta of 2.02. The company’s fifty day moving average price is $25.88 and its 200 day moving average price is $26.97.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. During the same quarter in the prior year, the firm posted $0.03 earnings per share. Moderna’s revenue for the quarter was down 45.4% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.